HIVE Blockchain Technologies (CVE:HIV – Get Free Report) was upgraded by investment analysts at Keefe, Bruyette & Woods to a “moderate buy” rating in a report issued on Wednesday,Zacks.com reports.
HIV has been the subject of a number of other research reports. Roth Capital raised shares of HIVE Blockchain Technologies to a “strong-buy” rating in a report on Wednesday, December 18th. Cantor Fitzgerald raised HIVE Blockchain Technologies to a “strong-buy” rating in a research report on Tuesday, October 29th. Finally, Northland Capmk upgraded HIVE Blockchain Technologies to a “strong-buy” rating in a research note on Thursday, September 19th. Four research analysts have rated the stock with a strong buy rating, Based on data from MarketBeat, HIVE Blockchain Technologies currently has a consensus rating of “Strong Buy”.
Get Our Latest Analysis on HIV
HIVE Blockchain Technologies Price Performance
Read More
- Five stocks we like better than HIVE Blockchain Technologies
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Consumer Staples Stocks, Explained
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for HIVE Blockchain Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HIVE Blockchain Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
